Antipsychotic Boxed Warning Will Caution Against Off-Label Use In Dementia

FDA is asking manufacturers of atypical antipsychotics to add a "black box" warning to labeling on an increased mortality risk associated with the drugs' off-label use to treat dementia-related behavioral disorders